As the second vaccine for Covid-19, Covovax is expected to be launched in June this year. Credit: torstensimon via Pixabay.

Serum Institute of India (SII) has announced plans to conduct clinical trials of another Covid-19 vaccine in the country, with hopes to launch it in June.

Covovax will be the second vaccine from SII (the first being Covishield) developed by Oxford-.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SII also noted that its partnership with for a Covid-19 vaccine showed excellent efficacy results and the company applied to begin trials in the country.

Last September, the company partnered with Novavax to manufacture one billion doses of the NVX-CoV2373 protein-based vaccine.

Separately, is reportedly seeking approval from the US Food and Drug Administration (FDA) to include up to five extra doses in each of the Covid-19 vaccine vials, which could speed up vaccine distribution.

The company is planning to increase the number of doses in each of the vials from ten to 15, CNBC reported.

Meanwhile, secured $16.5m in funding from the US Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support its ongoing Phase III trials of fostamatinib in Covid-19 patients.

The Phase III trial will evaluate the safety and efficacy of fostamatinib in patients without respiratory failure and have certain high-risk prognostic factors. It aims to enrol more than 300 patients administered with fostamatinib plus standard of care (SOC) or matched placebo plus SOC.

Speciality biopharmaceutical company RedHill announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase II / III study of opaganib in severe Covid-19 patients unanimously recommended to continue the study.

In another development, AstraZeneca secured a conditional marketing authorisation for its Covid-19 vaccine in the European Union (EU) for active immunisation in individuals aged 18 years and above.